WallStSmart
MENS

Jyong Biotech Ltd. Ordinary Shares

NASDAQ: MENS · HEALTHCARE · BIOTECHNOLOGY

$2.07
-3.81% today

Updated 2026-06-05

Market cap
$120.12M
P/E ratio
P/S ratio
EPS (TTM)
$-0.06
Dividend yield
52W range
$1 – $67
Volume
0.1M

WallStSmart proprietary scores

17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
5.0
Quality
C+
3.5
Profitability
D
5.0
Valuation
C+
5/9
Piotroski F-Score
Moderate
-4.1
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →199 stocks currently score above 75

Price targets

Analyst target
12-Month target
Intrinsic (DCF)
Margin of safety

Price chart

Stock snapshot

Strengths
+ Debt/equity -0.74x — low leverage
Risks
- Altman Z -4.07 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-3.04M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00
Net income$-6.63M$-4.40M$-3.02M$-4.67M$-3.42M
EPS$-0.06
Free cash flow$-3.22M$-2.60M$-3.62M$-3.04M$-3.04M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
MENS$120.12M174.33.55.05.0Avoid
LLY$1.01T7610.010.04.36.0Strong Buy
JNJ$567.28B574.79.03.36.0-67.79%Buy
ABBV$391.50B634.08.04.05.0-48.06%Buy
UNH$373.28B545.35.54.05.5-24.80%Buy
NVS$289.19B493.39.03.34.5-62.62%Hold

Smart narrative

Jyong Biotech Ltd. Ordinary Shares trades at $2.07. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -4.07, it sits in the distress.

Frequently asked questions

What is Jyong Biotech Ltd. Ordinary Shares's stock price?

Jyong Biotech Ltd. Ordinary Shares (MENS) trades at $2.07.

Is Jyong Biotech Ltd. Ordinary Shares overvalued?

Jyong Biotech Ltd. Ordinary Shares carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

Altman Z-Score?

Jyong Biotech Ltd. Ordinary Shares's Altman Z-Score is -4.07, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio
ROE
Beta
50D MA$2.20
200D MA$19.31
Shares out0.07B
Float0.03B
Short ratio
Avg volume0.1M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years